All In Biotech

Drug Trial Radar · NCT00235729

Lofexidine for Inpatient Opiate Detox

CSP #1024 - A Phase III, Randomized, Multi-Center, Double Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification.

Last checked: Nov 20, 2026Latest source record: Mar 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Jun 2006

Primary completion

Oct 2007

Study completion Oct 2007

Sponsor

Lead sponsor
US Department of Veterans AffairsFederal agency
Sponsor type
Federal agency
Collaborators
National Institute on Drug Abuse (NIDA); USWM, LLC (dba US WorldMeds)
First posted
Oct 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to investigate the effectiveness of lofexidine in reducing withdrawal symptoms among subjects undergoing opiate detoxification. Currently, lofexidine is the most commonly used non-opiate medication for detoxification from opiates in the United Kingdom (UK). There is no non-opiate medication approved by the Food and Drug Administration (FDA) for the same indication in the United States (US). The only medications currently approved by the FDA for opiate detoxification are methadone and buprenorphine. These medications, however, have the potential to be abused. Lofexidine, on the other hand, offers a unique advantage for opiate detoxification because it is not addicting, is easy to use, and has a favorable safety profile.

Conditions

  • Opiate Addiction

Interventions

  • LofexidineDrug

    Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.

  • PlaceboDrug

    Placebo is an exact match of lofexidine, less the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SOWS-Gossop score on Day 3 during the treatment phase & time-to-dropout for the subjects in the two treatment groups. during the treatment phase.Time frame: Day 3 of treatment phase for the SOWs score. Time to dropout will be measured as the number of 6-hour time quadrants until a subject withdraws or completes the treatment phase of the study

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • CNS, Cerritos

    Cerritos, California

  • CNS Psychiatric Institute of Washington

    Washington D.C., District of Columbia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Alexian Center for Psychiatric Research

    Hoffman Estates, Illinois

  • University of Kentucky

    Lexington, Kentucky

  • VA Maryland Health Care System, Baltimore

    Baltimore, Maryland

  • Wayne State University School of Medicine

    Detroit, Michigan

  • Richmond Medical Center

    Staten Island, New York

  • VA Medical Center, Philadelphia

    Philadelphia, Pennsylvania

  • VA Medical Center, Providence

    Providence, Rhode Island

  • Psychiatric Hospital at Vanderbilt

    Nashville, Tennessee

  • Research Across America

    Dallas, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • VA Salt Lake City Health Care System, Salt Lake City

    Salt Lake City, Utah

  • VA Puget Sound Health Care System, Seattle

    Seattle, Washington

  • Aurora Psychiatric Hospital

    Wauwatosa, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.